Provision of COVID-19 Convalescent Plasma in a Resource-Constrained State

Area of Science:

• Public Health
• Infectious Disease Management
• Hematology

Background:

• Arkansas, a rural state with high poverty, faced significant challenges during the COVID-19 pandemic.
• Approximately 8% of the state's population tested positive for COVID-19 since March 2020.
• Limited resources necessitated exploring innovative therapeutic options like COVID-19 convalescent plasma (CCP).

Purpose of the Study:

• To describe the development and implementation of the Arkansas Initiative for Convalescent Plasma (AICP).
• To ensure equitable access to potentially life-saving CCP therapy for all Arkansans.
• To highlight a collaborative, statewide approach to managing CCP resources.

Main Methods:

• A statewide collaborative response involving hospitals, blood collectors, and the Arkansas Department of Health (ADH).
• Early contact tracing by ADH to identify and monitor potential cases.
• Careful triage of CCP donors and robust resource/inventory management.

Main Results:

• Sufficient CCP units were collected to meet the demand for all treated patients in Arkansas.
• The initiative successfully provided CCP access statewide, despite initial resource limitations.
• Early identification of cases and prompt CCP collection were critical.

Conclusions:

• The Arkansas Initiative demonstrated the critical role of collaboration and resource management in delivering CCP therapy.
• A coordinated, statewide effort is essential to meet the demand for CCP products and save lives.
• Ensuring access to CCP in resource-limited settings is achievable through strategic partnerships.